Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | DHPS | P49366 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 3/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20426957 | 0.87 | MAPT (0.36) | CYP2A6MAPTPDK2PDE10ADHPS | |
| SCHEMBL20426875 | 0.85 | CYP1A2 (0.43) | CYP2A6MAPTPDK2CDC7CDK2 | |
| SCHEMBL20426876 | 0.84 | COMT (0.38) | CYP2A6MAPTPDK2CDC7CDK2 | |
| SCHEMBL20426891 | 0.84 | MAPT (0.43) | MAPTPDK2 | |
| SCHEMBL20426894 | 0.82 | PDK2 (0.37) | PDK2GSK3BCYP11B2 | |
| SCHEMBL20426896 | 0.81 | PDK2 (0.36) | CYP2A6MAPTPDK2DHPSGSK3B | |
| SCHEMBL20426878 | 0.81 | PDK2 (0.36) | CYP2A6PDK2DHPSGSK3BCYP11B2 | |
| SCHEMBL17017884 | 0.78 | CDC7 (0.35) | MAPTCDC7CDK2 | |
| SCHEMBL20426874 | 0.78 | MEN1 (0.31) | PDK2 | |
| SCHEMBL16943674 | 0.77 | MAPT (0.35) | CYP2A6MAPTPDK2PDE10ADHPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10038146-B2 | Organic light-emitting compound and organic electroluminescent device using same | DOOSAN CORPORATION (KR) | 2018-07-31 | — | — | US | disclosed |
| US-10038146-B2 | Organic light-emitting compound and organic electroluminescent device using same | DOOSAN CORPORATION (KR) | 2018-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10038146-B2 | Organic light-emitting compound and organic electroluminescent device using same | IDO1, IDO2, KYNU | CYP2A6 2126/4885MAPT 459/4885PDK2 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.